Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources


October 26, 2021

TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader

4th Annual TPD Summit
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
September 21, 2021

Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease

European Protein Degradation Congress
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
September 15, 2021

Inventing New Medicines with Targeted Protein Degradation

Undruggable Leaders Forum
Read More
July 12, 2021

Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL

13th Annual T-Cell Lymphoma Forum
PTCL
Read More
June 20, 2021

KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
MYD88 Tumors
Read More
May 26, 2021

Drugging Tissue-Restricted E3 Ligases

Ligase Targeting Drug Development Summit
Read More
May 10, 2021

IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints in Murine Models of IL-33/36- as well as Th17-driven Inflammation

American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
May 3, 2021

Multiple Mediators of Inflammation Correlate with IRAK4 Expression in the Skin of Hidradenitis Suppurativa Patients and are Blocked by the IRAK4 Degrader KT-474 in TLR-activated Monocytes

Society for Investigative Dermatology (SID) 2021 Annual Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
April 10, 2021

Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers

American Association of Cancer Research (AACR) 2021 Annual Meeting
MYD88 Tumors
Read More
February 16, 2021

Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties

Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC
Liquid Tumors Solid Tumors
Read More